Test Summary

The G-nAChR autoantibody assay can be used to identify Autoimmune Autonomic Ganglionopathy (AAG) or paraneoplastic AAG in patients with autonomic neuropathy. Identification of paraneoplastic AAG in a patient is important, as there is an association between increased levels of G-nAChR antibodies and small-cell lung cancer (SCLC) or thymoma. Detection of paraneoplastic AAG, followed by resection and/or treatment of the patients’ tumor, can lead to a successful patient recovery. The G-nAChR autoantibody assay can be used as a serological diagnostic tool to differentiate patients suffering from immmunotreatment-responsive AAG from idiopathic autonomic neuropathy. Both conditions can present as acquired Autonomic Nervous System (ANS) dysfunction characterized by diffuse autonomic nervous system failure. The demonstration of AAG can lead to a focused immunological treatment and successful patient recovery. The G-nAChR antibody assay can also identify patients with limited forms of dysmotility, diabetic autonomic neuropathy, or postural tachycardia syndrome.

Aliases

Specimen Collection

Special Instructions

Preferred Specimen

Minimum Volume

Instructions

Patient Preparation

Storage

Transport Temperature

Specimen Stability

Limitations

Other Acceptable Specimens

Unacceptable Specimens

Order Code

EPIC (Premier) Code

Includes

CPT Code

Billing Code

CPT Statement

Methodology

FDA Status

Physician Attestation of Informed Consent

Testing Laboratory

Reference Range

Setup Schedule / Expected Turnaround Time